- Assertio has endured a difficult few years that began with its $1.5bn purchase of opioid treatment Nucynta in 2015 under its former name DepoMed.
- Nucynta was sold for $375m to a buyer last year as the company swapped opioid treatments for NSAIDs. But much of the damage had already been done.
- Assertio announced a restructuring in December last year that reduced headcount by >100, to 27. New management is inexperienced but has done a good job settling debts.
- Its product portfolio is capable of generating >$100m sales per annum. But with no sales staff, perhaps the company is looking to be bought out.
- In this article I discuss how either a buyout or a turnaround represents a triple-digit upside opportunity for risk-on investors, as the threat of bankruptcy keeps the share price artificially low.
For further details see:
Assertio Holdings: Bankruptcy, Sale Or Success - How Management Can Rapidly Deliver Triple-Digit Upside